Literature DB >> 10516656

Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors.

R A Ross1, T M Gibson, L A Stevenson, B Saha, P Crocker, R K Razdan, R G Pertwee.   

Abstract

1. We have extended previous investigations of four analogues of Delta8-tetrahydrocannabinol (Delta8-THC): 6'-azidohex-2'-yne-Delta8-THC (O-1184), 6'-azidohex-cis-2'-ene-Delta8-THC (O-1238) and octyl-2'-yne-Delta8-THC (O-584) and its 1-deoxy-analogue (O-1315). 2. O-1184, O-1238 and O-584 displaced [3H]-CP55940 from specific binding sites on Chinese hamster ovary (CHO) cell membranes expressing CB1 or CB2 cannabinoid receptors, with pKi values of 8.28 to 8.45 (CB1) and 8.03 to 8.13 (CB2). The pKi values of O-1315 were significantly less, 7.63 (CB1) and 7.01 (CB2). 3. All the analogues inhibited forskolin-stimulated cyclic AMP production by CB1-transfected CHO cells (pEC50=9.16 to 9.72). Only O-1238 behaved as a full agonist in this cell line. 4. In mouse vasa deferentia, O-1238 inhibited electrically-evoked contractions (pEC50=10.18 and Emax=70.5%). Corresponding values for O-1184 were 9.08 and 21.1% respectively. At 1 nM, O-1184 produced surmountable antagonism of the cannabinoid receptor agonist, CP55940. However, at 0.1 nM, O-1184 did not attenuate CP55940-induced inhibition of cyclic AMP production by CB1-transfected CHO cells. 5. In CB2-transfected CHO cells, cyclic AMP production was inhibited by CP55940 (pEC50=8.59), enhanced by O-1184 and O-584 (pEC50=8.20 and 6.86 respectively) and not significantly affected by O-1238 or O-1315. 6. At 100 nM, O-1184 and O-1238 produced surmountable antagonism of CP55940 in CB2 cells, decreasing the pEC50 of CP55940 from 8.61 to 7.42 (O-1184) or from 8. 54 to 7.44 (O-1238). 7. These data support the hypothesis that increasing the degree of unsaturation of the aliphatic side-chain of Delta8-THC analogues has little effect on CB1 or CB2 receptor affinity but can reduce CB1 receptor efficacy and reverse the direction of responses elicited at CB2 receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516656      PMCID: PMC1571677          DOI: 10.1038/sj.bjp.0702836

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.

Authors:  J W Huffman; S Yu; V Showalter; M E Abood; J L Wiley; D R Compton; B R Martin; R D Bramblett; P H Reggio
Journal:  J Med Chem       Date:  1996-09-27       Impact factor: 7.446

Review 2.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

3.  Agonist-antagonist characterization of 6'-cyanohex-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations.

Authors:  R G Pertwee; S R Fernando; G Griffin; W Ryan; R K Razdan; D R Compton; B R Martin
Journal:  Eur J Pharmacol       Date:  1996-11-14       Impact factor: 4.432

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals.

Authors:  G Griffin; S R Fernando; R A Ross; N G McKay; M L Ashford; D Shire; J W Huffman; S Yu; J A Lainton; R G Pertwee
Journal:  Eur J Pharmacol       Date:  1997-11-19       Impact factor: 4.432

6.  An investigation into the structural determinants of cannabinoid receptor ligand efficacy.

Authors:  G Griffin; E J Wray; W K Rorrer; P J Crocker; W J Ryan; B Saha; R K Razdan; B R Martin; M E Abood
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

7.  A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.

Authors:  M Bouaboula; S Perrachon; L Milligan; X Canat; M Rinaldi-Carmona; M Portier; F Barth; B Calandra; F Pecceu; J Lupker; J P Maffrand; G Le Fur; P Casellas
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

8.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

9.  Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine.

Authors:  R G Pertwee; L A Stevenson; D B Elrick; R Mechoulam; A D Corbett
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

10.  Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.

Authors:  D M Slipetz; G P O'Neill; L Favreau; C Dufresne; M Gallant; Y Gareau; D Guay; M Labelle; K M Metters
Journal:  Mol Pharmacol       Date:  1995-08       Impact factor: 4.436

View more
  24 in total

1.  The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.

Authors:  Maria Grazia Cascio; Erica Zamberletti; Pietro Marini; Daniela Parolaro; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

2.  Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.

Authors:  Adèle Thomas; Lesley A Stevenson; Kerrie N Wease; Martin R Price; Gemma Baillie; Ruth A Ross; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

3.  AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.

Authors:  Daniele Bolognini; Maria Grazia Cascio; Daniela Parolaro; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Neocosmospora sp.-derived resorcylic acid lactones with in vitro binding affinity for human opioid and cannabinoid receptors.

Authors:  Jiangtao Gao; Mohamed M Radwan; Francisco León; Olivia Reed Dale; Afeef S Husni; Yunshan Wu; Shari Lupien; Xiaoning Wang; Susan P Manly; Robert A Hill; Frank M Dugan; Horace G Cutler; Stephen J Cutler
Journal:  J Nat Prod       Date:  2013-05-09       Impact factor: 4.050

5.  The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.

Authors:  Daniele Bolognini; Barbara Costa; Sabatino Maione; Francesca Comelli; Pietro Marini; Vincenzo Di Marzo; Daniela Parolaro; Ruth A Ross; Lisa A Gauson; Maria G Cascio; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

6.  Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine.

Authors:  A A Coutts; N Brewster; T Ingram; R K Razdan; R G Pertwee
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

7.  Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.

Authors:  Robert B Laprairie; Abhijit R Kulkarni; Pushkar M Kulkarni; Dow P Hurst; Diane Lynch; Patricia H Reggio; David R Janero; Roger G Pertwee; Lesley A Stevenson; Melanie E M Kelly; Eileen M Denovan-Wright; Ganesh A Thakur
Journal:  ACS Chem Neurosci       Date:  2016-04-25       Impact factor: 4.418

8.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.

Authors:  L Hanus; A Breuer; S Tchilibon; S Shiloah; D Goldenberg; M Horowitz; R G Pertwee; R A Ross; R Mechoulam; E Fride
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

9.  Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.

Authors:  M G Cascio; L A Gauson; L A Stevenson; R A Ross; R G Pertwee
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

10.  Discovery of Potent Dual PPARα Agonists/CB1 Ligands.

Authors:  Ruth Pérez-Fernández; Nieves Fresno; Manuel Macías-González; José Elguero; Juan Decara; Rocío Girón; Ana Rodríguez-Álvarez; María Isabel Martín; Fernando Rodríguez de Fonseca; Pilar Goya
Journal:  ACS Med Chem Lett       Date:  2011-09-16       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.